Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Roflumilast × Lymphoid × 1 year × Clear all
NCT06643221 2026-06-05

Allo-X

University of Arizona

Phase EARLY_PHASE1 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Motor Activity

NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡